Dianthus Therapeutics posts Q3 results and reports positive Phase 2 MaGic trial data in gMG
Reuters
Nov 06, 2025
Dianthus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts Q3 results and reports positive Phase 2 MaGic trial data in gMG
Dianthus Therapeutics Inc. reported a net loss of $36.8 million, or $0.97 per share, for the quarter ended September 30, 2025, compared to a net loss of $25.2 million, or $0.74 per share, for the same period in 2024. The company estimates an adjusted cash, cash equivalents, and investments position of approximately $525.0 million as of September 30, 2025, after accounting for upfront and near-term milestone payments related to the licensing of DNTH212 from Nanjing Leads Biolabs. This cash position is projected to provide funding runway into 2028. Recent business developments include the closing of an upsized public offering raising about $288.0 million and the exclusive licensing agreement for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569561-en) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.